ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,781.79
-0.21%
S&P 500
5,295.04
0.52%
Dow Jones
39,123.43
0.15%
US Dollar vs Yen
156.979
0.00%
Brent Oil
81.675
0.45%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Wave Life Sciences Ltd (WVE)

  7. Wave Life Sciences Ltd (WVE) ニュース

WVE

Wave Life Sciences (WVE)

Wave Life Sciences Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:WVE
日付受信時刻ニュースソース見出しコード企業名
2024/05/1020 : 30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:WVEWave Life Sciences Ltd
2024/05/0920 : 37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
2024/05/0920 : 30GlobeNewswire Inc.Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:WVEWave Life Sciences Ltd
2024/05/0920 : 00GlobeNewswire Inc.Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific OfficerNASDAQ:WVEWave Life Sciences Ltd
2024/05/0721 : 30GlobeNewswire Inc.Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:WVEWave Life Sciences Ltd
2024/05/0221 : 30GlobeNewswire Inc.Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024NASDAQ:WVEWave Life Sciences Ltd
2024/04/3021 : 30GlobeNewswire Inc.Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:WVEWave Life Sciences Ltd
2024/04/2321 : 30GlobeNewswire Inc.Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA EditingNASDAQ:WVEWave Life Sciences Ltd
2024/03/2721 : 30GlobeNewswire Inc.Wave Life Sciences to Present at Upcoming Investor ConferencesNASDAQ:WVEWave Life Sciences Ltd
2024/03/0621 : 55Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:WVEWave Life Sciences Ltd
2024/03/0621 : 39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
2024/03/0621 : 30GlobeNewswire Inc.Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:WVEWave Life Sciences Ltd
2024/02/2822 : 30GlobeNewswire Inc.Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024NASDAQ:WVEWave Life Sciences Ltd
2024/02/2722 : 30GlobeNewswire Inc.Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular DystrophyNASDAQ:WVEWave Life Sciences Ltd
2024/02/1306 : 15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:WVEWave Life Sciences Ltd
2024/02/0809 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WVEWave Life Sciences Ltd
2024/02/0809 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WVEWave Life Sciences Ltd
2024/02/0809 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WVEWave Life Sciences Ltd
2024/02/0809 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WVEWave Life Sciences Ltd
2024/01/0822 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
2024/01/0822 : 00GlobeNewswire Inc.Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 MilestonesNASDAQ:WVEWave Life Sciences Ltd
2024/01/0506 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
2024/01/0322 : 30GlobeNewswire Inc.Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:WVEWave Life Sciences Ltd
2023/12/1522 : 36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
2023/12/1522 : 30GlobeNewswire Inc.Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular DystrophyNASDAQ:WVEWave Life Sciences Ltd
2023/12/0820 : 06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WVEWave Life Sciences Ltd
2023/12/0811 : 26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WVEWave Life Sciences Ltd
2023/12/0721 : 00GlobeNewswire Inc.Wave Life Sciences Prices $100 Million Public Offering of Ordinary SharesNASDAQ:WVEWave Life Sciences Ltd
2023/12/0706 : 13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WVEWave Life Sciences Ltd
2023/12/0706 : 10GlobeNewswire Inc.Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:WVEWave Life Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:WVE

最近閲覧した銘柄

BIT
UC4KTV
Unicredit Bank
NASDAQ
BLMN
Bloomin Brands
BIT
UC4VD8
Unicredit Bank
KUCN
TRADEUSDT
USOTC
ALIF
Artificial Life (CE)
BOV
FESA3Q
FERBASA ON
LSE
WNDG
Gx Wind Energy
LSE
GSL
KOSPI
002870
Shinpoong
LSE
0M6J
H+h International A/s
BIT
UC69CL
Unicredit Bank
UNSW
MAFIETH
Mafia.Network
BIT
UC5R48
Unicredit Bank
BMF
DDIF27
DDIF27 - Janeiro 2027
BIT
S29788
Societe Generale Effekten
AMEX
XLEY
Cushing Energy and MLP ETF
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有